#top-leaderboard-ads, .stickyads { position: static !important; }

From Pathway to Patient Response in Atopic Dermatitis

Featuring:

E(Elizabeth (Lisa) Swanson, MDFaculty

Updated:Oct 28, 2026

Atopic Dermatitis

About this video

Understanding how a therapy works is one thing. Seeing how that mechanism may translate into clinical improvement is another. Lisa Swanson, MD, connects the multiple actions of tapinarof to the outcomes observed in pivotal studies of patients with moderate-to-severe atopic dermatitis, including improvements in Investigator Global Assessment (IGA) scores, Eczema Area and Severity Index (EASI) scores, and itch.

Her discussion offers a useful perspective on why addressing several contributors to atopic dermatitis simultaneously may matter, and how that understanding can inform the way clinicians approach topical treatment.

Continuing Education

0.75 Credits

Charting the Course to Higher Targets With JAK Inhibition in Atopic Dermatitis

In this 45-minute symposium, expert faculty cover the latest updates for JAK inhibitors, including head-to-head efficacy and safety data for JAK inhibitors and biologics, and share clinical pearls for using JAK inhibitors in dermatology practice for atopic dermatitis."I can say that in my clinic, I am reaching for those high bars. You have toput yourself in the position of the patient or imagine that patient is your family member. Would you want mediocre treatment for them or average treatment or moderate treatment? You’d want them to get the best possible treatment. In my practice I’m now counseling patients 'yes we want clear skin. Yes, we want minimal itch. Yes we want your skin pain gone and for you to sleep better.'”- David Cotter, MD, PhDFC25: Charting the Course to Higher Targets With JAK Inhibition in Atopic Dermatitis: An Online ActivityThis activity is supported by an educational grant from AbbVie.

0.75 Credits

Illuminate the Role of IL-13 Inhibitors for the Management of Atopic Dermatitis

Don’t miss this Satellite Symposium from the 2025 Fall Clinical Dermatology Conference®, as Dr. Alexandra Golant, Dr. Mona Shahriari, and Dr. G. Michael Lewitt discuss IL-13 targeting biologics in the treatment of atopic dermatitis as well as strategies for optimizing their use.“To me, coming into an exam room in 2025, when we have so many different treatment options for these patients, it's a unique opportunity to use what we know about the data of these therapeutics and walk patients though their options and how to understand their disease state, and how to best choose the therapy that feels right for them.” – Alexandra Golant, MD  FC25: Illuminate the Role of IL-13 Inhibitors for the Management of Atopic DermatitisThis activity is supported by an educational grant from Lilly.

0.25 Credits

HowTo’ Treat the Toughest Spots: Tackling Head and Neck Atopic Dermatitis

“Of course we’re always starting with our basics: we’re using our gentle cleansers, our moisturization, our avoidance of known allergens or triggers, and then we're doing our topicals. But it can be very difficult if you have heavy stuff on your face or you’re required to put it on over and over. It can be really tough. So this paves the way really nicely to say it is time to move up, it is time to think about the next level, and typically the next step up is going to be a biologic agent.” - Peter Lio, MDA ‘HowTo’ activity delivers a short burst of engaging and compact content for learners to study at their own convenience. This microlearning activity is intended to provide practical insights from two experts on ‘HowTo’ improve care in head and neck atopic dermatitis in 10 minutes.This activity is supported by an educational grant from LEO Pharma.